Heart failure drug levosimendan tested for long-term safety in 35 patients

NCT ID NCT03624010

Completed Disease control Sponsor: Tenax Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety of using levosimendan over a longer period in people who have both pulmonary hypertension and heart failure with preserved ejection fraction. 35 patients who had already been in a related study received the drug and were monitored for side effects. The main goal was to see how many adverse events occurred.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH NORMAL EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cor pulmonale diastolic heart failure pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH NORMAL EJECTION FRACTION HYPERTENSION PULMONARY SECONDARY HEART FAILURE RIGHT SIDED HEART FAILURE WITH NORMAL EJECTION FRACTION

Contacts and locations

Show contact details

Locations

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Stanford Healthcare

Stanford, California, 94305, United States
UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, 15213, United States
UW Health University Hospital

Madison, Wisconsin, 53792, United States
University of Minnesota Medical Center

Minneapolis, Minnesota, 55455, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.